GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Cash Flow from Financing

Opthea (FRA:UKJ) Cash Flow from Financing : €224.76 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Opthea Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, Opthea received €97.90 Mil more from issuing new shares than it paid to buy back shares. It spent €0.03 Mil paying down its debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It spent €0.00 Mil on other financial activities. In all, Opthea earned €97.87 Mil on financial activities for the six months ended in Jun. 2024.


Opthea Cash Flow from Financing Historical Data

The historical data trend for Opthea's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Cash Flow from Financing Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.46 97.06 0.16 154.40 226.42

Opthea Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 157.83 0.08 126.90 97.87

Opthea Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Opthea's Cash from Financing for the fiscal year that ended in Jun. 2024 is calculated as:

Opthea's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €224.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opthea  (FRA:UKJ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Opthea's issuance of stock for the six months ended in Jun. 2024 was €97.90 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Opthea's repurchase of stock for the six months ended in Jun. 2024 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Opthea's net issuance of debt for the six months ended in Jun. 2024 was €-0.03 Mil. Opthea spent €0.03 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Opthea's net issuance of preferred for the six months ended in Jun. 2024 was €0.00 Mil. Opthea paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Opthea's cash flow for dividends for the six months ended in Jun. 2024 was €0.00 Mil. Opthea received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Opthea's other financing for the six months ended in Jun. 2024 was €-0.00 Mil. Opthea spent €0.00 Mil on other financial activities.


Opthea Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Opthea's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea Business Description

Industry
Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines